nach oben

Targeted Oncology

Erschienen in:

01.06.2011 | Review

Common toxicities of mammalian target of rapamycin inhibitors

verfasst von: Scott A. Soefje, Anand Karnad, Andrew J. Brenner

Erschienen in: Targeted Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.

Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef

Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347PubMedCrossRef

Atkins MB, Hildalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918PubMedCrossRef

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef

O’Donnell A, Faivre S, Burris HA III et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595PubMedCrossRef

Hartford CM, Berk L, Loewry JW et al (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428–1434PubMedCrossRef

Mita MM, Mita AC, Chu QS et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361–367PubMedCrossRef

Mahe E, Morelon E, Lechaton S et al (2005) Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79:476–482PubMedCrossRef

Sonis S, Treister N, Chawla S, Demetri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210–215PubMed

10.

Campistol JM, de Fijter JW, Flechner SM et al (2010) mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 24:149–156PubMedCrossRef

11.

Fouladi M, Lanningham F, Wu J et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812PubMedCrossRef

12.

Chuang P, Langone AJ (2007) Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 7:714–717PubMedCrossRef

13.

Morelon E, Stern M, Israël-Biet D et al (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72:787–790PubMedCrossRef

14.

Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77:1215–1220PubMedCrossRef

15.

Duran I, Sui LL, Oza AM et al (2004) Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875–1880CrossRef

16.

Aparicio G, Calvo MB, Medina V et al (2009) Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol 11:499–510PubMedCrossRef

17.

Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent Glioblastoma Multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294–5304PubMedCrossRef

18.

Beretta L, Gingras AC, Svitkin YV et al (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15:658–664PubMed

19.

Taha C, Liu Z, Jin J et al (1999) Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. J Biol Chem 274(46):33085–33091PubMedCrossRef

20.

Rizzieri DA, Feldman E, DiPersio JF et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14:2756–2762PubMedCrossRef

21.

Executive Summary: Standards of Medical Care in Diabetes—2011. Diabetes Care 34:S4–S10

22.

Brattstrom C, Wilczek H, Tyden G et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65:1272–1274PubMedCrossRef

23.

Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118:1094–1101PubMedCrossRef

24.

Torisel (2010) Package insert. Wyeth Pharmaceuticals, Philadelphia

25.

Afinitor (2010) Package insert. Novartis Pharmaceuticals Corporation, East Hanover

Titel: Common toxicities of mammalian target of rapamycin inhibitors
verfasst von: Scott A. Soefje
Anand Karnad
Andrew J. Brenner
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 2/2011
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0174-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Common toxicities of mammalian target of rapamycin inhibitors

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Are we ready to move away from nature? The rapamycin story

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie